Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples